Different Candida Oral Drugs Have Similar Results
Itraconazole and fluconazole have similar success and adverse outcome rates
WEDNESDAY, Feb. 13 (HealthDay News) -- Treating acute uncomplicated vaginal or vulvovaginal candidiasis in non-pregnant women with either itraconazole or fluconazole produces similar results, according to the results of a study published in the February issue of the American Journal of Obstetrics & Gynecology.
Eleni Pitsouni, M.D., and colleagues at the Alfa Institute of Biomedical Sciences in Athens, Greece, conducted a review of six randomized controlled trials comprising 1,092 patients with vaginal or vulvovaginal candidiasis to assess the differences in outcome between itraconazole and fluconazole, both orally administered triazole antifungal agents.
When the two drugs were compared in terms of clinical cure and improvement, mycologic cure, adverse events affecting the digestive and nervous systems, and adverse events severe enough to cause withdrawal from treatment, the two drugs produced similar results. Two trials provided data on the rate of recurrence, which was 9 percent for fluconazole and 13 percent for itraconazole.
"The results of this meta-analysis suggest that itraconazole and fluconazole for the treatment of non-pregnant women with acute uncomplicated vaginal/vulvovaginal candidiasis have similar effectiveness and safety. Future randomized controlled trials on this population may focus on the effect of these antifungal agents on the probability of symptomatic recurrences," the authors conclude.